Study Results Suggest That ORKAMBI Can Have an Impact for up to 2 Years
The possible benefits and risks of treatment with ORKAMBI in people age 12 years and older with 2 copies of the F508del mutation were studied in 2 Short-Term Studies of 24 weeks. People who completed these studies could then participate in a Long-Term Study for an additional 96 weeks.
Below, you'll find more details on how ORKAMBI was studied, as well as the study results. All of the results shown for each study below are an average of all people evaluated in each study.
Studied up to 2 Years
2 Short-Term Studies
1 Long-Term Study
The possible benefits and risks of treatment with ORKAMBI were studied for up to 2 years in people with cystic fibrosis (CF) age 12 and older.
- In the Short-Term Studies, ORKAMBI and placebo (sugar pill) were compared. In the Long-Term Study, all participants took ORKAMBI
- Every 12 hours, participants took 2 tablets of ORKAMBI (lumacaftor 200 mg/ivacaftor 125 mg) or placebo, with fat-containing food, along with their other prescribed CF treatments
- The Long-Term Study did not have any participants who took placebo. All patients knew they were taking ORKAMBI, which may have influenced the results
- The FDA did not consider the Long-Term Study when approving ORKAMBI, and it is not included in the full Prescribing Information. The Long-Term Study may not meet the FDA’s definition of an acceptable study because there was no placebo group included for comparison
- Before the Long-Term Study concluded at 96 weeks, about half of participants left the study for reasons other than side effects; most of these participants left after Week 72 of the Long-Term Study, when ORKAMBI was approved by the FDA
Lung Function Improved in Both Studies
2.6 Percentage Points
3.0 Percentage Points
Lung Function Maintained Above
Where It Was Before Treatment
BMI Increased in Both Studies
+0.7 pounds for a person
who is 5'4" and weighs 110 lbs
+2.4 pounds for a person
who is 5'4" and weighs 110 lbs
BMI Increased Over Time
Survey Scores Showed Some Improvement
in Both Studies
Survey Scores Varied Over Time
PEs Were Less Likely in Both Studies
A Reduction in the Number of PEs Per Year Was Maintained Over Time
From a separate analysis combining
the results of both Short-Term Studies*
56% less likely to have a PE that requires intravenous antibiotics
61% less likely to have a PE that requires hospitalization
*This analysis was not planned as part of the original study, nor is it included in the full Prescribing Information. It cannot be determined if the observed changes were due to ORKAMBI.
Change the Way Your Child’s CF Is Treated
The primary purpose of the study below was to determine the safety of ORKAMBI in children age
with 2 copies of the F508del-CFTR mutation.
The Study Evaluated:
Lung function is measured with an FEV1 test, which measures how much air a person can exhale in a forced breath. Lung function was part of the safety assessment in this trial.
Children with CF have high levels of sweat chloride (mmol/L), which is a measure of the amount of salt in a child’s sweat. Children with sweat chloride levels of less than 30 mmol/L are unlikely to have CF.
The side effects from this study were similar to what was observed in studies of ORKAMBI in older people. See the side effects here >>>
After taking ORKAMBI for 24 weeks, lung function increased and sweat chloride levels decreased.
After ORKAMBI was stopped, changes were seen in lung function and sweat chloride levels.
Because patients did not take placebo, no comparisons could be made. It is not known if changes in lung function and sweat chloride levels were due to ORKAMBI. Changes in sweat chloride levels are not related to changes in lung function.
Long-term studies with ORKAMBI have not yet been completed in people age 6 through 11 years.
As the holidays approach, don’t forget to fill your prescription!
Keep in mind that pharmacies may have limited hours and delivery schedules during the holidays. Don’t forget to plan ahead to make sure you have enough medicine on hand.